Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 10, 2014, Pages 1655-1660

  Kim, Mun Ock ^a   Lee, Suui ^a   Choi, Kwangman ^a   Lee, Sangku ^a   Kim, Hyeongki ^a,b   Kang, Hyunju ^a   Choi, Miri ^a   Kwon, Eun Bin ^a   Kang, Myung Ji ^a   Kim, Sunhong ^a,b   Lee, Hyun Jun ^a   Lee, Hyun Sun ^a   Kwak, Young Shin ^c   Cho, Sungchan ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea University   (South Korea)

Author keywords

Diacylglycerol acyltransferase 2 (DGAT2); Metabolic disease; Small molecule inhibitor; Triacylglycerol

Indexed keywords

ACYLTRANSFERASE INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; H 2 001; H 2 002; H 2 003; H 2 004; H 2 005; H 2 006; H 2 007; H 2 008; N (6 MORPHOLINOPYRIDIN 3 YL) 1 PHENYL 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 4 CARBOXAMIDE; UNCLASSIFIED DRUG; 1H-PYRROLO(2,3-B)PYRIDINE-3-ACETIC ACID; ACETIC ACID DERIVATIVE; DGAT2 PROTEIN, MOUSE; DIACYLGLYCEROL ACYLTRANSFERASE; PYRIDINE DERIVATIVE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; IC50; IN VITRO STUDY; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; PROTEIN EXPRESSION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DEVELOPMENT; HEK293 CELL LINE; HEPG2 CELL LINE; HUMAN; METABOLISM; MOUSE; PROCEDURES;

3T3-L1 CELLS; ACETATES; ANIMALS; DIACYLGLYCEROL O-ACYLTRANSFERASE; DRUG DISCOVERY; HEK293 CELLS; HEP G2 CELLS; HUMANS; MICE; PYRIDINES;

EID: 84908052356     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00447     Document Type: Article

References (22)

1. Coleman RA, Lee DP. Enzymes of triacylglycerol synthesis and their regulation. Prog. Lipid Res., 43, 134-176 (2004).
2. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipiddroplets in metabolic disease in rodents and humans. J. Clin. Invest., 121, 2102-2110 (2011).
3. Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J. Lipid Res., 50 (Suppl.), S74-S79 (2008).
4. Tziomalos K, Athyros VG, Karagiannis A, Kolovou GD, Mikhailidis DP. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr. Drug Targets, 10, 320-327 (2009).
5. Turchetto-Zolet AC, Maraschin FS, de Morais GL, Cagliari A, Andrade CM, Margis-Pinheiro M, Margis R. Evolutionary view of acyl-CoA diacylglycerol acyltransferase (DGAT), a key enzyme in neutral lipid biosynthesis. BMC Evol. Biol., 11, 263 (2011).
6. Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J. Lipid Res., 49, 2283-2301 (2008).
7. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese RV Jr. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J. Biol. Chem., 279, 11767-11776 (2004).
8. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet., 25, 87-90 (2000).
9. Chen HC, Rao M, Sajan MP, Standaert M, Kanoh Y, Miura A, Farese RV Jr, Farese RV. Role of adipocyte-derived factors in enhancing insulin signaling in skeletal muscle and white adipose tissue of mice lacking acyl CoA : diacylglycerol acyltransferase 1. Diabetes, 53, 1445-1451 (2004).
10. Choi CS, Savage DB, Kulkarni A, Yu XX, Liu ZX, Morino K, Kim S, Distefano A, Samuel VT, Neschen S, Zhang D, Wang A, Zhang XM, Kahn M, Cline GW, Pandey SK, Geisler JG, Bhanot S, Monia BP, Shulman GI. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem., 282, 22678-22688 (2007).
11. Levin MC, Monetti M, Watt MJ, Sajan MP, Stevens RD, Bain JR, Newgard CB, Farese RV Sr, Farese RV Jr. Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. Am. J. Physiol. Endocrinol. Metab., 293, E1772-E1781 (2007).
12. Millar JS, Stone SJ, Tietge UJ, Tow B, Billheimer JT, Wong JS, Hamilton RL, Farese RV Jr, Rader DJ. Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J. Lipid Res., 47, 2297-2305 (2006).
13. Harris CA, Haas JT, Streeper RS, Stone SJ, Kumari M, Yang K, Han X, Brownell N, Gross RW, Zechner R, Farese RV Jr. DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes. J. Lipid Res., 52, 657-667 (2011).
14. Jornayvaz FR, Birkenfeld AL, Jurczak MJ, Kanda S, Guigni BA, Jiang DC, Zhang D, Lee HY, Samuel VT, Shulman GI. Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc. Natl. Acad. Sci. U.S.A., 108, 5748-5752 (2011).
15. Qi J, Lang W, Geisler JG, Wang P, Petrounia I, Mai S, Smith C, Askari H, Struble GT, Williams R, Bhanot S, Monia BP, Bayoumy S, Grant E, Caldwell GW, Todd MJ, Liang Y, Gaul MD, Demarest KT, Connelly MA. The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT-1 and -2. J. Lipid Res., 53, 1106-1116 (2012).
16. Lee K, Kim M, Lee B, Goo J, Kim J, Naik R, Seo JH, Kim MO, Byun Y, Song GY, Lee HS, Choi Y. Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors. Org. Biomol. Chem., 11, 849-858 (2013).
17. Kim MO, Lee SU, Lee HJ, Choi K, Kim H, Lee S, Oh SJ, Kim S, Kang JS, Lee HS, Kwak YS, Cho S. Identification and validation of a selective small molecule inhibitor targeting the diacylglycerol acyltransferase 2 activity. Biol. Pharm. Bull., 36, 1167-1173 (2013).
18. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J. Biol. Chem., 268, 6823-6826 (1993).
19. Schober G, Arnold M, Birtles S, Buckett LK, Pacheco-Lopez G, Turnbull AV, Langhans W, Mansouri A. Diacylglycerol acyltransferase- 1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats. J. Lipid Res., 54, 1369-1384 (2013).
20. Seppälä-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab., 87, 3023-3028 (2002).
21. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (Baltimore), 45, 1366-1374 (2007).
22. Liu Y, Millar JS, Cromley DA, Graham M, Crooke R, Billheimer JT, Rader DJ. Knockdown of acyl-CoA : diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim. Biophys. Acta, 1781, 97-104 (2008).